1. Mild encephalopathy with reversible splenium lesion (MERS) in a patient with COVID-19
- Author
-
Jaffer Ahmed, Todd Siegal, Tudor G Jovin, Bhavika Kakadia, and Jesse M. Thon
- Subjects
Pathology ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Encephalopathy ,Clinical Neurology ,Splenium ,Mild encephalopathy with reversible splenium lesion ,medicine.disease_cause ,Article ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,MERS ,Physiology (medical) ,medicine ,Coronavirus ,biology ,medicine.diagnostic_test ,SARS-CoV-2 ,business.industry ,COVID-19 ,Magnetic resonance imaging ,General Medicine ,biology.organism_classification ,medicine.disease ,Neurology ,030220 oncology & carcinogenesis ,Surgery ,Neurology (clinical) ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Betacoronavirus - Abstract
Highlights • Mild encephalopathy with reversible splenium lesion (MERS) is a condition characterized by fever, encephalopathy, and a reversible splenium lesion on brain MRI. • MERS has been previously associated with viral infections, such as the influenza virus, and may result from an immune-mediated response to infection. • MERS has not previously been described in conjunction with COVID-19. • We present a case of a patient with MERS and positive SARS-CoV-2 antibodies, the first reported instance of this neurological complication to the virus. • MERS should be considered in a patient with the characteristic clinico-radiological syndrome and COVID-19 infection., Neurological complications of coronavirus 2019 (COVID-19) are common, and novel manifestations are increasingly being recognized. Mild encephalopathy with reversible splenium lesion (MERS) is a syndrome that has been associated with viral infections, but not previously with COVID-19. In this report, we describe the case of a 69 year-old man who presented with fever and encephalopathy in the setting of a diffusion-restricting splenium lesion, initially mimicking an ischemic stroke. A comprehensive infectious workup revealed positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, and a pro-inflammatory laboratory profile characteristic of COVID-19 infection. His symptoms resolved and the brain MRI findings completely normalized on repeat imaging, consistent with MERS. This case suggests that MERS may manifest as an autoimmune response to SARS-CoV-2 infection and should be considered in a patient with evidence of recent COVID-19 infection and the characteristic MERS clinico-radiological syndrome.
- Published
- 2020